Ministry of Public Health Thailand (MoPH)
Ministry of Public Health of Thailand (MoPH) is the structural Thai ministry overseeing public-health policy, hospital licensing, disease control, and the national health system. Houses the Food and Drug Administration (Thai FDA), Department of Disease Control (DDC), Department of Medical Services (DMS), and Department of Health Service Support. Coordinates the 30-Baht Universal Coverage Scheme with the National Health Security Office (NHSO). Drives Thailand's medical-hub and medical-tourism strategy, including the Medical Hub Master Plan. Regulates the private-hospital sector alongside the Healthcare Business Committee.
Snapshot
Headline numbers a buyer checks first.
Established
1942
Ongoing
Public hospitals under MOPH
~1,000+
2024
Annual budget
~THB 180 bn
FY2024
Universal Health Coverage population
~48 M
2024
Profile overview
Ministry of Public Health of Thailand (MoPH) is the structural Thai ministry overseeing public-health policy, hospital licensing, disease control, and the national health system. Houses the Food and Drug Administration (Thai FDA), Department of Disease Control (DDC), Department of Medical Services (DMS), and Department of Health Service Support. Coordinates the 30-Baht Universal Coverage Scheme with the National Health Security Office (NHSO). Drives Thailand's medical-hub and medical-tourism strategy, including the Medical Hub Master Plan. Regulates the private-hospital sector alongside the Healthcare Business Committee.
Departments and functions
Regulation
Thai FDA and drug scheduling
Food and Drug Administration (FDA) under MoPH licenses pharmaceuticals, medical devices, food, cosmetics, and controlled substances. Cannabis scheduling decision (2022 decriminalisation, 2024 reschedule) was an FDA-driven MoPH policy exercise with major commercial implications.
Universal coverage
30-Baht UC Scheme coordination
Coordinates the 30-Baht Universal Coverage Scheme with NHSO covering ~48 million Thais. Scheme costs ~ $5.8B annually; MoPH's hospital-licensing and service-standard regulations determine capacity utilisation and quality across 11,000 public health facilities.
Disease control
Department of Disease Control
DDC oversees disease surveillance, outbreak response, and immunisation programmes. COVID-19 management demonstrated DDC's central role in travel policy, mandatory testing requirements, and vaccine-procurement decisions that materially affected Thai tourism and aviation sectors.
Medical hub
Medical Hub Master Plan
MoPH coordinates Thailand's Medical Hub strategy targeting USD 8B in medical-tourism receipts by 2027. Licensing of JCI-accredited private hospitals, visa-on-arrival for medical treatment, and telemedicine regulation are key policy instruments.
Thai healthcare system at a glance
Key indicators, 2024
UC Scheme beneficiaries
Value
~48M
Note
30-Baht universal coverage
Public hospitals
Value
~1,000+
Note
MoPH-operated
Public health centres
Value
~10,000
Note
Sub-district level
Private hospitals (licensed)
Value
~350+
Note
MoPH-regulated
Medical tourists (2024)
Value
~2.5M
Note
Target USD 8B receipts by 2027
Healthcare spend (% GDP)
Value
Note
Public-sector dominant
| Indicator | Value | Note |
|---|---|---|
| UC Scheme beneficiaries | ~48M | 30-Baht universal coverage |
| Public hospitals | ~1,000+ | MoPH-operated |
| Public health centres | ~10,000 | Sub-district level |
| Private hospitals (licensed) | ~350+ | MoPH-regulated |
| Medical tourists (2024) | ~2.5M | Target USD 8B receipts by 2027 |
| Healthcare spend (% GDP) | ~4% | Public-sector dominant |
Key drivers 2025-2026
Demographics
Ageing population demand surge
Thailand's over-65 population reaches 20% by 2030. MoPH long-term care policy, geriatric hospital capacity expansion, and community-health-volunteer coverage for elderly in rural areas are the dominant budget and policy challenges through 2030.
Cannabis
Recriminalisation and medical tier
MoPH's November 2024 Narcotic Act amendment recriminalised recreational cannabis. Medical and research-use licensing through Thai FDA remains the legal framework. Private hospital and clinic investment in cannabis-based treatment programmes depends on MoPH regulatory clarity.
Medical hub
Post-COVID medical tourism rebuild
Medical tourist numbers recovering toward 2019 peak (3M+). MoPH facilitates international-patient visa processing and hospital accreditation. Chinese and Middle East medical tourist targets require Arabic and Mandarin clinical-service capability investments by licensed hospitals.
Where this profile is featured
Reports that reference this entity in their operator concentration or analysis.
Featured in
Thai Cannabis: From 2022 Decriminalisation to 2025 Recriminalisatio...
Cannabis scheduling authority; June 2022 decriminalisation, Nov 2024 reschedule.
Featured in
Thai Aging 65+ Trajectory and Fertility Collapse: Economic Impact
Healthcare-demand-projection driver.
Featured in
Thai Cannabis: Decriminalisation Rollback and the Medical-Tier Future
Healthcare-demand-projection driver.
Related Market profiles
Peers, parents, partners, agencies, and other Hospitals & Medical Tourism actors.
Competitor
Bumrungrad Hospital
Thailand's medical-tourism flagship — first Asian hospital JCI-accredited (2002); >60% international-patient revenue mix.
Open Market profile →
Competitor
Bangkok Dusit Medical Services
Thailand's largest listed hospital group — 50+ hospitals across six brand families; > $3.19B FY2024 revenue.
Open Market profile →
Competitor
Bangkok Chain Hospital
Mid-market listed hospital operator — Kasemrad brand across 15+ hospitals; SSS, UCS contract-heavy franchise.
Open Market profile →
Sector peer
Asian Cosmetic Surgery Center
Bangkok cosmetic surgery center serving domestic and international patients.
Open Market profile →
Reports featuring this profile
Thai Cannabis: From 2022 Decriminalisation to 2025 Recriminalisation and the Industry Whiplash
Cannabis scheduling authority; June 2022 decriminalisation, Nov 2024 reschedule.
Open report →
Sits alongside 5 other Atlas profilesThai Aging 65+ Trajectory and Fertility Collapse: Economic Impact
Healthcare-demand-projection driver.
Open report →
Sits alongside 4 other Atlas profilesThai Cannabis: Decriminalisation Rollback and the Medical-Tier Future
Healthcare-demand-projection driver.
Open report →
Sits alongside 5 other Atlas profilesRelated Market profiles
competitor
Bumrungrad Hospital
Thailand's medical-tourism flagship — first Asian hospital JCI-accredited (2002); >60% international-patient revenue mix.
competitor
Bangkok Dusit Medical Services
Thailand's largest listed hospital group — 50+ hospitals across six brand families; >THB 110B FY2024 revenue.
competitor
Bangkok Chain Hospital
Mid-market listed hospital operator — Kasemrad brand across 15+ hospitals; SSS, UCS contract-heavy franchise.